A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia

Journal of Clinical Psychiatry

Volumn 57, Issue 4, 1996, Pages 167-173

  Lohr, James B ^a,b   Caligiuri, Michael P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSKINESIA; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; MALE; MOTOR DYSFUNCTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RATING SCALE; RISK ASSESSMENT; TARDIVE DYSKINESIA; VOLUNTARY MOVEMENT;

ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; PHYSICAL EXAMINATION; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMIN E;

EID: 0029994643     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. American Psychiatric Association. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: APA; 1992
2. Bird ED. Collins GH, Dodson MH, et al. The effect of phenothiazine on the manganese concentration in the basal ganglia of sub-human primates. In: Barbeau A, Bumette J-R, eds. Progress in Neuro-Genetics. Amsterdam, The Netherlands: Excerpta Medica; 1967:600-605
3. Weiner WJ, Nausieda PA, Klawans HL. Effect of chlorpromazine on central nervous system concentrations of manganese, iron, and copper. Life Sci 1977;20:1181-1186
4. Hunter R, Blackwood W, Smith MC, et al. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication. J Neurol Sci 1968;7-263-273
5. Campbell WG, Raskind MA, Gordon T, et al. Iron pigment in the brain of a man with tardive dyskinesia. Am J Psychiatry 1985;142:364-365
6. Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107-108
7. Lohr JB, Cadet JL, Lohr MA, et al. Alpha-tocopherol in tardive dyskinesia: a preliminary study. Lancet 1987;1:913-914
8. Bartzokis G, Garber HJ, Marder SR, et al. MRI in tardive dyskinesia: shortened left caudate T2. Biol Psychiatry 1990;28:1027-1036
9. Horrobin DF, Manku MS, Morse-Fisher N, et al. Essential fatty acids in plasma phospholipids in schizophrenics. Biol Psychiatry 1989;5:562-568
10. Lohr JB, Kuczenski R, Bracha HS, et al. Increased indices of free radical activity m the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990;28:535-539
11. Sram RJ, Binkova B, Kocisova J, et al. Antioxidants effect on alcohol, drugs, and aging. In: Mendelsohn ML, Albertini RJ, eds. Mutation and the Environment. New York, NY: Wiley-Liss; 1990:327-337
12. Cohen G. Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989;26:689-690
13. Shivakumar BR, Ravindranath V. Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol. Brain Res 1992;595:256-262
14. Tsai G, Goff D, Coyle JT. Oxidative stress and glutamatergic hypotheses of tardive dyskinesia [abstract]. Soc Neurosci Abstr 1994;20:1647
15. Lohr JB, Cadet JL, Lohr MA, et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988;14:291-296
16. Elkashef AM, Ruskin PE, Bacher N, et al. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990;147:505-506
17. Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesias with vitamin E. Eur Psychiatry 1991;6:201-207
18. Egan MF, Hyde T, Albers G, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773-777
19. Shriqui CL, Bradwejn J, Annable L, et al. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992;149:391-393
20. Spivak B, Schwartz B, Radwan M, et al. Alpha-tocopherol treatment for tardive dyskinesia. J Nerv Ment Dis 1992;180:400-401
21. Junker D, Steigleider P, Gattaz WF. Alpha-tocopherol in the treatment of tardive dyskinesia. Clin Neuropharmacol 1992;15(suppl 1, pt b):639B
22. Akhtar S, Jajor TR, Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med 1993;39:124-126
23. Adler L, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dys-kinesia. Am J Psychiatry 1993;150:1405-1407
24. Peet M, Laugharne J, Rangarajan N, et al. Tardive dyskinesia. lipid peroxidation and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993;8:151-153
25. Lam LCW, Chiu HFK, Hung SF. Vitamin E in the treatment of tardive dys-kinesia: a replication study. J Nerv Ment Dis 1994;182:113-114
26. Dabiri LM, Pasta D, Darby JK, et al. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 1994;151:925-926
27. Caligiuri MP, Lohr JB. A potential mechanism underlying the voluntary suppression of tardive dyskinesia. J Psychiatr Res 1989;23:257-266
28. Caligiuri MP, Lohr JB. Fine force instability: a quantitative measure of hand dyskinesia. J Neuropsychiatry Clin Neurosci 1990;2:395-398
29. Lohr JB, Browning JA. Free radical involvement in neuropsychiatrie illnesses. Psychopharmacol Bull 1995;31:159-165
30. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487
31. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988;39: 1172-1177
32. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-19
33. Bigelow LB, Berthot BA. The psychiatric assessment scale. Psychopharmacol Bull 1989;25:168-179
34. Bergen JA, Eyland EA, Campbell JA, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 1989;154: 523-528
35. Barnes TRE, Rossor M, Trauer T. A comparison of purposeless movements in psychiatric patients treated with antipsychotic drugs, and normal individuals. J Neurol Neurosurg Psychiatry 1983;46:540-546
36. Caligiuri MP, Lohr JB, Vaughan RM, et al. Fluctuation of tardive dyskinesia Biol Psychiatry 1995;38:336-339
37. Lohr JB, Caligiuri MP. Quantitative instrumental measurement of tardive dyskinesia: a review Neuropsychopharmacology 1992;6:231-239
38. Golse B, Debray Q, Puget K, et al. Dosage erythrocytaire de la superoxyde dismutase 1 et de la glutathion peroxydase dans les schizophrenies de l'adulte. Nouvelle Presse Medicale 1978;23:2070-2071
39. Prilipko LL. Activation of lipid peroxidation under stress and in schizophrenia. In: Kemali D, Morozov PV, Toffano G, eds. New Research Strategies in Biological Psychiatry. Biological Psychiatry - New Prospects, vol 3. London, England: John Libbey; 1984
40. Abdalla DSP, Monteiro HP, Oliveira JAC, et al. Activities of Superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986;32:805-807
41. Gattaz WF, Kollisch M, Thuren T, et al. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 1987;22:421-426
42. 2 activity in schizophrenia: a replication study. Biol Psychiatry 1990;28:495-501
43. Reddy R, Sahebarao MP, Mukherjee S, et al. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991; 30:409-412
44. Beauclair L, Vinogradov S, Riney SJ, et al. An adjunctive role for ascorbic acid in the treatment of schizophrenia? J Clin Psychopharmacol 1987;7: 282-283
45. Straw GM, Bigelow LB, Kirch DG. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid. J Clin Psychopharmacol 1989;9:130-132
46. Gattaz WF, Emrich A, Behrens S. Vitamin E attenuates the development of neuroleptic-induced dopaminergic hypersensitiviry in rats: implications for tardive dyskinesia. Clin Neuropharmacol 1992;15(suppl 1, pt b):267B
47. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Bull 1992;8: 93-102
48. Dixon L, WeidenPJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992;33:121-122
49. Nordmann R, Ribiere C, Rouach H. Implication of free radical mechanisms in ethanol-induced cellular injury. Free Radic Biol Med 1992;12: 219-240
50. Sawada M, Sester U, Carlson JC. Superoxide radical formation and associated biochemical alterations in the plasma membrane of brain, heart, and liver during the lifetime of the rat. J Cell Biochem 1992;48:296-304
51. Joseph JA. The putative role of free radicals in the loss of neuronal functioning in senescence. Integr Physiol Behav Sci 1992;27:216-227